Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nuffield Council on Bioethics consultation.

Peter Lipton1

  • 1Nuffield Council on Bioethics, UK. bioethics@nuffieldfoundation.org

Pharmacogenomics
|January 9, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modeling molecular pathways of neuronal ischemia.

Progress in molecular biology and translational science·2014
Same author

Lysosomal membrane permeabilization as a key player in brain ischemic cell death: a "lysosomocentric" hypothesis for ischemic brain damage.

Translational stroke research·2013
Same author

Lysosomal release of cathepsins causes ischemic damage in the rat hippocampal slice and depends on NMDA-mediated calcium influx, arachidonic acid metabolism, and free radical production.

Journal of neurochemistry·2008
Same author

The Medawar Lecture 2004 the truth about science.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2005
Same author

Testing hypotheses: prediction and prejudice.

Science (New York, N.Y.)·2005
Same author

Pharmacogenetics: ethical problems and solutions.

Nature reviews. Genetics·2004
Same journal

Closely similar tacrolimus morning troughs and graft function across the recipients' common <i>ABCB1</i> polymorphisms (<i>c.2677G>T/A</i>, <i>c.1236C>T</i>, <i>c.3435C>T</i>) early after renal transplantation.

Pharmacogenomics·2026
Same journal

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.

Pharmacogenomics·2026
Same journal

Guidance from an informed public on collecting and sharing PGx test results for major depressive disorder: "It's no different from your blood type".

Pharmacogenomics·2026
Same journal

Optimizing pharmacogenomics workflows: a qualitative evaluation of clinical service delivery models.

Pharmacogenomics·2026
Same journal

Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases.

Pharmacogenomics·2026
Same journal

Practical guide to implementing pre-emptive pharmacogenetic screening in routine pediatric oncology care.

Pharmacogenomics·2026
See all related articles

Pharmacogenetics enables personalized medicine by predicting drug response, improving treatment efficacy and safety. However, ethical and regulatory challenges must be addressed for widespread clinical adoption.

Area of Science:

  • Biotechnology
  • Genomics
  • Pharmacology

Background:

  • Pharmacogenetics offers potential for personalized medicine, tailoring treatments to individual genetic profiles.
  • Genetic analysis can predict patient response to medications, aiming for optimal drug efficacy and safety.
  • The Human Genome Project provides foundational data for advancing pharmacogenetic applications.

Purpose of the Study:

  • To explore the potential of pharmacogenetics in revolutionizing medicine.
  • To examine the ethical, legal, social, and regulatory implications of personalized medicine.
  • To inform the development of guidelines for the responsible implementation of pharmacogenetics.

Main Methods:

  • Review of current pharmacogenetic research and its clinical applications.
Keywords:
Biomedical and Behavioral ResearchGenetics and ReproductionNuffield Council on Bioethics

Related Experiment Videos

  • Analysis of ethical, legal, and social issues associated with genetic testing for drug response.
  • Examination of regulatory considerations for targeted prescription.

    • Main Results:

    • Pharmacogenetic tests show promise for improving drug efficacy and reducing adverse side effects.
    • Significant ethical, legal, social, and regulatory challenges impede the clinical realization of personalized medicine.
    • A working party has been established to address these complex issues.

    Conclusions:

    • Personalized medicine, guided by pharmacogenetics, holds great promise but requires careful consideration of its broader impacts.
    • Addressing ethical, legal, social, and regulatory concerns is crucial for the successful integration of pharmacogenetics into healthcare.
    • Further dialogue and policy development are needed to navigate the complexities of targeted prescription.